Clinical study of oral propranolol treatment for pediatric hemangioma and lymphangioma

Clinical study of oral propranolol treatment for pediatric hemangioma and lymphangioma - Clinical study of oral propranolol treatment for pediatric hemangioma and lymphangioma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004453

Enrollment

Registered

2010-10-26

Start date

2010-10-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric hemangioma and lymphangioma

Interventions

oral propranolol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: intractable hemangioma and lymphangioma

Exclusion criteria

Exclusion criteria: Heart disease and hypotension. Patient who has drug allergy, and patient with the past of serious side effect by the propranolol drug. Patient who was considered ineligible by the investigators.

Design outcomes

Primary

Measure	Time frame
Improvement of symptoms. SIde effects.	—

Countries

Japan

Contacts

Public ContactMichio Ozeki

Gifu University Graduate School of Medicine Department of Pediatrics

michioo@gifu-u.ac.jp058-230-6000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026